Another Positive Phase III For Lilly's, Incyte's Baricitinib
This article was originally published in Scrip
Eli Lilly & Co. and Incyte Corp. reported on Sept. 29 that baricitinib bested the first-line rheumatoid arthritis (RA) standard of care methotrexate in a late-stage clinical trial, so now the partners must complete just one more Phase III trial before seeking regulatory approvals for the JAK inhibitor.
You may also be interested in...
During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.